• Novel Drug Product Creation with new composition-of-Matter IP

    Our technology is a powerful Intellectual Property (IP) engine

Topical therapies are the therapeutic pillar for many diseases, but traditional water- or oil-based formulations have significant limitations that may influence efficacy and safety.

EyeSol® is the worldwide first and only water-free technology for ophthalmic products. It dramatically increases the residual time on the eye from seconds to hours and enables high bioavailability of active pharmaceutical ingredients (API) with excellent tolerability and safety while reducing systemic exposure due to a small drop size (<12 µL).

Thereby EyeSol® unlocks the full potential of APIs by generating novel drug products often even with new Composition of Matter IP. The technology is clinically validated, safe and well accepted.

Our products have the potential to redefine drug therapies. Refer to Products or Pipeline for more insight on how EyeSol® overcomes the limitations in eye care therapies

Ophthalmology – Clinical Stage Development Programs

Program Drug Indication Disc. Pre-clinic Phase I Phase II Phase III Reg. Market Milestones
CyclASol® (cyclosporine A) Dry Eye Disease, anti-inflammatory USA
CHN
ESSENCE-2 top line data in 2021;
US NDA submission 2022
NOV03 (perfluorohexyloctane) Dry Eye Disease, associated with MGD* USA
CHN
Developed by: Bausch+Lomb (USA);
Hengrui Medicine (China)
BTQ 1901 / BTQ 1902 (timolol, nebivolol) Glaucoma, beta-blockers USA US clinical phase starts in 2021;
Developed with Betaliq Inc.
Program CyclASol® (cyclosporine A) NOV03 (perfluorohexyloctane) BTQ 1901 / BTQ 1902 (timolol, nebivolol)
Drug Indication Dry Eye Disease, anti-inflammatory Dry Eye Disease, associated with MGD Glaucoma, beta-blockers
Disc.
Pre-clinic
Phase I
Phase II
Phase III
Reg.
Market USA, CHN USA, CHN USA
Milestones ESSENCE-2 top line data 2021; US NDA submission 2022 Developed by: Bausch+Lomb (USA); Hengrui Medicine (China) US clinical phase starts in 2021; Developed with Betaliq Inc.

* MGD = Meibomian Gland Dysfunction

Approved CE products: Novatears®, Novatears®+Omega-3